Kanna Microdosing: What It Means and What Is Known
'Microdose' is a vendor term with no standard definition for kanna. Here is what studies actually used, what labels say, and what nobody has tested.
Kanna microdosing turns up in search results, vendor pages and magazine features, usually as if the term had a clear meaning. It does not. "Microdose" was borrowed from psychedelic research and stuck onto kanna by marketers, and there is no agreed milligram line between "micro" and anything else. This post explains the term, shows the low doses that human studies actually used, explains why "micro" does not mean small, and lists what has never been tested. We do not recommend a dose or a schedule.
A kanna "microdose" has no standard definition. The term comes from psychedelic research, where definitions are inconsistent [1]; for kanna it is a vendor label, defined in each company's own units, often mg of mesembrine. Human trials used 8 mg and 25 mg of one standardized extract [2][3] (one 6-week trial also used 50 mg [12]), and no study has compared "micro" against larger amounts or tested any schedule.
What does microdosing mean?
It originally meant taking very small amounts of a psychedelic substance, but even there the definition is unsettled.
A 2022 systematic review in Neuroscience & Biobehavioral Reviews examined 44 studies of low-dose psychedelics published between 1955 and 2021. The authors said they attempted to clarify definitional inconsistencies in the microdosing literature by suggesting dose ranges for different substances, and they noted that study quality varied widely [1]. So even in the field the word came from, "micro" is a matter of convention, set against each substance's typical dose.
That reference point is the problem for kanna. There is no recognized "full dose" of kanna to take a fraction of. The word microdosing also carries psychedelic associations that do not fit. The mechanisms proposed for kanna in the research we reviewed are serotonin-transporter blockade and PDE4 inhibition in lab work [8], which is not how classic psychedelics are described. We use "microdosing" in this post because people search for it, not because it is a scientific category for kanna.
How do vendors define a kanna microdose?
Each company draws its own line, in its own units, often milligrams of mesembrine.
Some vendors state a microdose in mg of mesembrine, others in mg of extract, and the definitions do not have to match each other or any scientific threshold. We found no trial evidence behind any vendor's definition, and we are not endorsing or recommending any amount. If a product calls itself a microdose, ask what the number refers to: extract weight, mesembrine, or total alkaloids.
What low doses have human studies used?
Small ones: 8 mg, 25 mg and (in one trial) 50 mg of a standardized extract, none labeled as microdosing.
| Study | Amount of extract | Length | Participants |
|---|---|---|---|
| Nell 2013, safety trial [2] | 8 mg or 25 mg once daily | 3 months | 37 healthy adults |
| Chiu 2014, cognition [3] | 25 mg once daily | 3 weeks | 21 adults aged 45 to 65 |
| Hoffman 2020 [4] | 25 mg once daily | 8 days | 60 recreationally trained adults |
| Dimpfel 2017, EEG [12] | 25 mg or 50 mg once daily | 6 weeks | 60 healthy adults aged 50 to 80 |
| Terburg 2013, brain imaging [5] | 25 mg | Single dose | 16 healthy adults |
| Reay 2020, anxiety tasks [6] | 25 mg | Single dose | 20 healthy volunteers across two studies |
Most of these trials used a 2:1 standardized extract called Zembrin; the Chiu paper describes its capsule as standardized to 0.4% total alkaloids [3]. A 2026 critical review notes small samples and mixed results across this literature [9]. The trials were short, in healthy people, and several involved authors affiliated with the extract's owner. They do not show that these amounts are right for anyone, and they were not designed to compare a low amount against a higher one. For results, see what the research on kanna shows. For labeled amounts in drinks, see kanna dosage.
Why can't the numbers be compared?
Because "micro" on a vendor label does not mean "below the amounts that were studied."
The Chiu trial's 25 mg capsule was standardized to 0.4% total alkaloids [3], which works out to roughly 0.1 mg of total alkaloids (25 mg times 0.004). That is our arithmetic from the paper's figure, and we did not verify it against another source. A vendor "microdose" stated in mg of mesembrine can contain far more alkaloid than that. So a product sold as a microdose may deliver more than the trial capsules did. Drink labels add another layer: some state extract weight, some state alkaloids, and some state nothing about standardization. We cover this in our guide to kanna per can and the label guide.
The practical lesson: a number printed on a bottle is only meaningful in context. Without knowing the extract, the standardization and the unit, "10 mg" tells you very little.
What is known and unknown about kanna microdosing?
A few trial doses are documented; nearly everything else people claim is untested.
| Claim or question | Status |
|---|---|
| Standardized extract at 8 or 25 mg daily was tolerated for 3 months in 37 healthy adults | Reported, small trial [2] |
| A "microdose" has a standard size | No: vendor-defined |
| Microdosing outperforms larger amounts, or vice versa | No study compares them |
| Intermittent schedules (some days on, some off) change anything | No kanna study found |
| Lower amounts reduce interaction risk | Not established; interactions are "not fully understood" [7] |
| Lower amounts avoid tolerance | Untested; see kanna tolerance |
| Effects of small amounts in people with anxiety or other conditions | Not studied; trials were in healthy volunteers [9][10] |
Terms like "sub-perceptual" or "functional microdose" also appear in marketing. With kanna, we found no study that measured whether participants could perceive a given amount. A 2021 review notes that the plant had not been studied in a clinical population [10]. So anyone presenting microdosing as an established method, with schedules, cycles and stacking, is describing practices that come from online communities and from psychedelic culture rather than from kanna research.
What safety points apply at any amount?
The same ones that apply to kanna generally, regardless of what a product calls its amount.
- Medicines. WebMD lists possible interactions between sceletium and SSRIs, SNRIs, MAOIs, tricyclics, antipsychotics, triptans and St. John's wort, and says interactions are not fully understood [7]. Talk to a doctor or pharmacist before using kanna if you take any of these. We have no data showing that a small amount avoids the concern.
- Pregnancy and nursing. WebMD says it is not known whether sceletium is safe in pregnancy [7]. Ask a clinician.
- Product variation. WebMD notes products may vary in content [7], and a 2016 lab analysis found an undeclared stimulant, ephedrine, in one commercial kanna sample [11].
- No approvals. The FDA has not reviewed or approved sceletium [7].
For the broader picture see is kanna safe, and for how often and how long, how long kanna lasts. If you are comparing forms, our post on kanna drinks vs capsules explains the formats.
This page is general information, not medical advice, and does not recommend any dose or schedule. These statements have not been evaluated by the FDA. Kanna products are not intended for any disease or health condition. kannadrinks.com is published by Psilly Goose, a kanna drink maker.
References
- Polito V, Liknaitzky P. The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev 2022;139:104706. PubMed
- Nell H, et al. A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults. J Altern Complement Med 2013;19(11):898-904. PubMed
- Chiu S, et al. Proof-of-concept randomized controlled study of cognition effects of the proprietary extract Sceletium tortuosum (Zembrin) targeting phosphodiesterase-4 in cognitively healthy subjects. Evid Based Complement Alternat Med 2014;2014:682014. PMC
- Hoffman JR, et al. Ergogenic effects of 8 days of Sceletium tortuosum supplementation on mood, visual tracking, and reaction in recreationally trained men and women. J Strength Cond Res 2020;34(9):2476-81. PubMed
- Terburg D, et al. Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology 2013;38(13):2708-16. PubMed
- Reay J, et al. Sceletium tortuosum (Zembrin) ameliorates experimentally induced anxiety in healthy volunteers. Hum Psychopharmacol 2020;35(6):1-7. PubMed
- WebMD. Sceletium: Uses, side effects, interactions. webmd.com
- Harvey AL, et al. Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. J Ethnopharmacol 2011;137(3):1124-9. PubMed
- de Jong M, et al. Mesembryanthemum tortuosum and Zembrin: mixed evidence from in vivo animal and clinical studies on their antidepressant and anxiolytic effects. Planta Med 2026;92(8):806-823. PubMed
- Olatunji TL, et al. Sceletium tortuosum: a review on its phytochemistry, pharmacokinetics, biological and clinical activities. J Ethnopharmacol 2021;280:114476. PubMed
- Lesiak AD, et al. Direct analysis in real time high resolution mass spectrometry as a tool for rapid characterization of mind-altering plant materials and revelation of supplement adulteration: the case of Kanna. Forensic Sci Int 2016;260:66-73. PubMed
- Dimpfel W, Gericke N, Suliman S, Chiegoua Dipah GN. Effect of Zembrin on brain electrical activity in 60 older subjects after 6 weeks of daily intake. World J Neurosci 2017;7(1):140-171. SCIRP
Frequently asked questions
What is a kanna microdose?
There is no standard definition. The term is borrowed from psychedelic research, where it is loosely defined and inconsistent [1]. Vendors define a kanna microdose in their own units, often mg of mesembrine, so one company's microdose may not match another's. Those are labels, not scientific thresholds, and this site does not recommend an amount.
What doses have been used in kanna studies?
Human trials used 8 mg and 25 mg of a standardized extract called Zembrin, as a single dose or once daily for 8 days to 3 months [2][3][4][5][6], plus one 6-week trial at 25 or 50 mg daily (Dimpfel 2017) [12]. They were not described as microdosing studies, and the numbers are extract weight, not alkaloid weight.
Is there a kanna microdosing schedule?
No schedule has been tested for kanna that we could find. Any schedule you see online is untested. This site does not recommend a dose or schedule; see kanna dosage.
Is a smaller amount of kanna safer?
Unknown. The only safety trial we found tested 8 mg and 25 mg daily for 3 months and reported good tolerability in 37 healthy adults [2]. No study compares lower and higher amounts for safety, and interactions with serotonin-affecting medicines are a concern at any amount [7].
Is kanna a psychedelic?
The sources we reviewed describe kanna's proposed mechanisms as serotonin-transporter and PDE4 activity [8], not classic psychedelic receptor activity. The word microdosing comes from psychedelic culture, but that does not make kanna one.